### SYNTHESIS OF 21-[82Br]-21-DEOXYURIDINE

#### Y.W. Lee, E.E. Knaus and L.I. Wiebe Division of Bionucleonics and Radiopharmacy University of Alberta Edmonton, Alberta; Canada T6G 2N8

#### SUMMARY

Reaction of 2,2<sup>1</sup>-anhydrouridine (<u>2</u>) with [ $^{82}Br$ ]-ammonium bromide in the presence of one equivalent <u>p</u>-toluenesulfonic acid afforded 2<sup>1</sup>-[ $^{82}Br$ ]-2<sup>1</sup>-deoxyuridine (<u>3</u>) in 73.4% chemical yield with a specific activity of 0.58 mCi mM<sup>-1</sup>. Alternatively, direct activation of 2<sup>1</sup>-bromo-2<sup>1</sup>-deoxyuridine at a thermal neutron flux of 1 x 10<sup>12</sup>n cm<sup>-2</sup>s<sup>-1</sup> gave 2<sup>1</sup>-[ $^{82}Br$ ]-2<sup>1</sup>deoxyuridine, with a specific activity of 0.6-0.7 mCi mM<sup>-1</sup> for a 3 hr irradiation. 2<sup>1</sup>-[ $^{82}Br$ ]-2<sup>1</sup>-deoxyuridine was rapidly purified by high pressure liquid chromatography with an elution time of 18 minutes, or by preparative thin layer chromatography.

Key Words: <sup>82</sup>Br-Labeled Radiopharmaceutical, 2<sup>1</sup>-Bromo-2<sup>1</sup>-deoxynucleoside, High Pressure Liquid Chromatography.

#### INTRODUCTION

It is well documented that the hydrogen or hydroxyl substituent on the  $2^{1}$ -carbon of nucleic acids is the distinguishing feature between deoxyribonucleic (DNA) and ribonucleic acids (RNA). The differential distribution and tumor uptake of the radiohalogenated thymidine analogs  $5-[^{18}F]-2^{1}$ deoxyuridine (1),  $5-[^{82}Br]-2^{1}$ -deoxyuridine (2,3) and  $5-[^{131}I]-2^{1}$ -deoxyuridine (4) in mice have been reported. The results of these studies prompted investigation of nucleosides having a radiohalogen rather than a hydrogen or hydroxyl substituent at the 2<sup>1</sup>-position of the sugar moiety. The ultimate goal of this study is to determine the potential of 2<sup>1</sup>-radiohalogenated nucleosides for use in diagnostic oncology, specifically the non-invasive measurement of biochemical activity within a tumor before, during and after therapy. We now report (5) the synthesis of  $2^{1}-[^{82}Br]-2^{1}$ -deoxyuridine  $(2^{1}-[^{82}Br]-2^{1}-UdR)$ .


The rationale for selecting  $2^{1}-[^{82}Br]-2^{1}-UdR$  for this study was: (i) Bromine-82 (T $_{2}=35.4$  hr) is readily available and is a suitable model for bromine-77 (T $_{2}=56$  hr) (6,7); (ii) Incorporation of bromine into the  $2^{1}$ position is less difficult than fluorine or iodine; (iii) the C-Br bond is 10-15 kcal/mol stronger than the corresponding C-I bond and hence the label is more stable (8).

#### RESULTS AND DISCUSSION

Reaction of uridine (<u>1</u>) with diphenylcarbonate using the procedure of Hampton and Nichol (9) gave rise to  $2,2^1$ -anhydrouridine (<u>2</u>) in 58% yield. Treatment of <u>2</u> with bromide anion in the presence of one equivalent of <u>p</u>-toluenesulfonic acid in dimethylformamide at 100° for 4 hr afforded 2<sup>1</sup>bromo-2<sup>1</sup>-deoxyuridine (<u>3</u>). The yield of <u>3</u> using ammonium, sodium and lithium bromide, as determined by quantitative preparative high pressure liquid chromatography (HPLC), was 62, 80 and 70% respectively. The reaction of <u>2</u> with alkalai metal bromides did not proceed in the absence of <u>p</u>-toluenesulfonic acid. The latter was likely required for protonation of the 2,2<sup>1</sup>-anhydro ether linkage of <u>2</u> to yield the protonated intermediate <u>4</u> which subsequently reacts with bromide anion due to the increased

# Synthesis of $2^{1} - \begin{bmatrix} 82 \\ Br \end{bmatrix} - 2^{1} - Deoxyuridine$

electrophilicity of the  $2^1$ -position (8). The  $2^1$ -bromo substituent of  $\underline{3}$  was present in the <u>ribo</u>-configuration since  $\underline{3}$  was identical (mp,ir,ms,nmr) to an authentic sample of known configuration (10) prepared from the reaction of 2 with anhydrous hydrogen bromide (8).



Reaction of 2,2<sup>1</sup>-anhydrouridine (<u>2</u>) with 11.5 equivalents [ $^{82}Br$ ]ammonium bromide in the presence of one equivalent <u>p</u>-toluemesulfonic acid at 100° for 6.5 hr gave 2<sup>1</sup>-[ $^{82}Br$ ]-2<sup>1</sup>-deoxyuridine (<u>3</u>) in 73.4% chemical yield with a specific activity of 0.582 mCi mM<sup>-1</sup> (6.3% radiochemical yield). The direct irradiation of <u>3</u> in the University of Alberta Slowpoke reactor was also carried out using the  ${}^{81}Br(n,\gamma)$   ${}^{82}Br$  reaction at a neutron flux of 1 x  $10^{12}n$  cm<sup>-2</sup>s<sup>-1</sup>. The irradiated product <u>3</u> was allowed to stand for 24 hr to allow  ${}^{80m}Br(T_2=4.4 hr)$  to decay since natural abundance ammonium bromide was used in the synthesis.

Quantitative high pressure liquid chromatographic (HPLC) separation and purification of the reaction mixture or the irradiated product  $\underline{3}$  was carried out as illustrated in Figure 1. Preparative thin layer chromatography was equally effective for purifying and quantitating  $\underline{3}$ . Radiolytic decomposition due to reactor irradiation of  $\underline{3}$  was substantial since 25% of the  $2^{1}$ -Br- $2^{1}$ -deoxyuridine was recovered 24 hr after the end of bombardment by HPLC or TLC purification. However TLC separation and counting indicated that only 19.3 ±2.4% of the total [ $^{82}$ Br]-radioactivity produced was present in  $2^{1}$ -[ $^{82}$ Br]- $2^{1}$ -deoxyuridine after irradiations of  $\underline{3}$  at 1 x  $10^{12}$ n cm<sup>-2</sup>s<sup>-1</sup> for 1-3 hr. Excessive radiolysis was observed (sample discoloring) after longer irradiation periods. The specific activity of  $2^{1}$ -[ $^{82}$ Br]- $2^{1}$ deoxyuridine for a 3 hr irradiation was 0.6-0.7 mCi mM<sup>-1</sup> at the end of bombardment.

The reaction of 2,2<sup>1</sup>-anhydrouridine ( $\underline{2}$ ) with alkalai metal bromides is a general and efficient reaction for the synthesis of  $\underline{3}$  having radiobromine at the 2<sup>1</sup>-position. Although the reaction of  $\underline{2}$  with [<sup>77</sup>Br]-NH<sub>4</sub>Br has not been carried out it would provide <sup>77</sup>Br - labeled  $\underline{3}$ . It is expected that reaction of  $\underline{2}$  with [<sup>81</sup>Br]-NH<sub>4</sub>Br (97% enriched; Oakridge National Laboratory) would give radiobrominated  $\underline{3}$  with twice the specific activity after direct irradiation. Elimination of the decay period




FIG. 1. RADIO HIGH PRESSURE LIQUID CHROMATOGRAM OF 2<sup>1</sup>-[<sup>82</sup>Br]-2<sup>1</sup>-deoxyuridine after reactor irradiation of 3. Column: E. Merck Silica Gel 60 prepacked Size B; 2.5 x 26 cm Solvent: MeOH:CHCL<sub>3</sub> (1:1 v/v) Flow Rate: 5 mL/min U.V. Detection: 254 nm Radioactivity Detector: NAI (TL) detector A. <sup>82</sup>Br-radioactivity recording of column eluant B. Ultraviolet spectrometry recording of column eluant required to allow decay of <sup>80m</sup>Br would then give an effective usable activity of almost 4 times that reported here for similar production procedures.

#### EXPERIMENTAL

 $2^{1}$ -Bromo- $2^{1}$ -deoxyuridine. A solution of 2,2<sup>1</sup>-anhydrouridine (51.2mg, 0.227 mmol), ammonium bromide (50.6 mg, 0.516 mmol) and <u>p</u>-toluenesulfonic acid (39.1 mg, 0.227 mmol) in 5 ml dry dimethylformamide was heated at 100° for 4 hr. The solvent was removed <u>in vacuo</u>, 20 ml acetone was added to the residue and the insoluble material was removed by filtration. Removal of the acetone <u>in vacuo</u> gave a syrup-like liquid which was partitioned between 5 ml water and 10 ml benzene. Removal of the water <u>in vacuo</u> from the aqueous fraction gave <u>3</u> which was dissolved in 2 ml methanol. Quantitative preparative high pressure liquid chromatography using a E. Merck Silica gel 60 prepacked Size B column using methanol:chloroform (1:1 v/v) as solvent with a flow rate of 5 ml/min and U.V. detection at 254 nm gave 2<sup>1</sup>-bromo-2<sup>1</sup>-deoxyuridine (62%) with an elution time of 18 min. Removal of the solvent <u>in vacuo</u> gave <u>3</u> as a white solid which was identical (mp,ir,nmr,ms) with an authentic sample (8).

Reaction of 2 (77.9 mg, 0.34 mmol), sodium bromide (0.191 g, 1.86 mmol) and <u>p</u>-toluenesulfonic acid (58.5 mg, 0.34 mmol) in 5 ml dry dimethylformamide followed by quantitative high pressure liquid chromatography as described above afforded  $2^1$ -bromo- $2^1$ -deoxyuridine (80%).

Similarly, reaction of 2 (45.6 mg, 0.2 mmol), lithium bromide (34.7 mg, 0.4 mmol) and <u>p</u>-toluenesulfonic acid (34.4 mg, 0.2 mmol) in 5 ml dry dimethyl-formamide followed by quantitative high pressure liquid chromatography as

# Synthesis of $2^{1} - \begin{bmatrix} 8^{2} \\ Br \end{bmatrix} - 2^{1} - Deoxyuridine$

described above gave  $2^1$ -bromo- $2^1$ -deoxyuridine (70%).

 $[^{82}Br]$ -Ammonium bromide. A solution of  $[^{81}Br]$ -NaBr (100 mg, 97.81% enriched in 81-bromine, Oak Ridge National Laboratory) in 1 ml deionized distilled water was added to a cation (ammonium) exchange column containing 50 g Amberlite IR-120 (Mallinckrodt Chemical Works). Elution with 25 ml deionized distilled water, removal of the solvent and drying <u>in vacuo</u> gave  $[^{81}Br]$ -NH<sub>4</sub>Br. Titrimetric analysis of the product for ammonium and bromide indicated an ammonium:bromide ratio of 0.8:1 (11). Neutron activation analysis indicated the sodium line of 2754 keV to be less than 1% of the total activity. The  $[^{81}Br]$ -NH<sub>4</sub>Br was used without further purification. Irradiation of  $[^{81}Br]$ -NH<sub>4</sub>Br in the University of Alberta Slowpoke Reactor using the  $^{81}Br$  (n, $_{Y}$ )  $^{82}Br$  reaction at a neutron flux of 1 x 10<sup>12</sup>n cm<sup>-2</sup>s<sup>-1</sup> gave routine radiation yields of 9 uCi mg<sup>-1</sup>hr<sup>-1</sup> of  $[^{82}Br]$ -NH<sub>4</sub>Br. The  $[^{82}Br]$ -NH<sub>4</sub>Br produced was used, after standing for 4 hr, without further purification.

### 2<sup>1</sup>-[<sup>82</sup>Br]-2<sup>1</sup>-deoxyuridine

<u>Method A: Reaction with [82Br]-NH4Br</u>. A solution of 2,21-anhydrouridine (3.6 mg, 0.016 mmol), [82Br]-ammonium bromide (18 mg, 0.18 mmol, 2 hr irradiation with a neutron flux of 1 x  $10^{12}$ n cm<sup>-2</sup>s<sup>-1</sup>) and <u>p</u>-toluenesulfonic acid (2.7 mg, 0.018 mmol) in 0.2 ml dry dimethylformamide was heated at 100° for 6.5 hr. After cooling in an ice bath the solution was applied to one 20 x 20 cm silica gel DSF-5 plate 1.0 mm in thickness which was developed using chloroform: 1,4-dioxane: methanol (8:6:3 v/v) as development solvent. The Rf values for pure samples of  $[^{82}Br]-NH_4Br$ , 2,2<sup>1</sup>-anhydrouridine, uridine and  $[^{82}Br]-2^1$ -deoxyuridine (<u>3</u>) were 0, 0.17, 0.41 and 0.60 respectively. Extraction of the fraction having Rf 0.60 with warm methanol (50 ml) and quantitation using ultraviolet adsorption spectrometry at 260 nm (MeOH) indicated a 73.4% chemical yield of <u>3</u> (3.6 mg) with a specific activity of 0.582 mCi mM<sup>-1</sup> as determined by liquid scintillation counting (6.3% radiochemical yield).

<u>Method B: Direct irradiation of 2<sup>1</sup>-bromo-2<sup>1</sup>-deoxyuridine</u>. A 2 mg sample of 2<sup>1</sup>-bromo-2<sup>1</sup>-deoxyuridine (<u>3</u>) (containing natural abundance bromine) was irradiated in a double plastic vial using the  ${}^{81}\text{Br}(n,\gamma){}^{82}\text{Br}$  reaction in the University of Alberta Slowpoke Reactor at a neutron flux of  $10^{12}n$  cm<sup>-2</sup>s<sup>-1</sup> for 3 hr. After standing for 24 hr the irradiated sample was dissolved in 1 ml methanol and was then purified using preparative quantitative high pressure liquid chromatography as described above (See Figure 1) to give  $2^{1}-[{}^{82}\text{Br}]-2^{1}$ -deoxyuridine (25% chemical recovery). The specific activity was 0.6-0.7 mCi mM<sup>-1</sup> as determined by liquid scintillation counting (Corrected to the end of bombardment).

#### ACKNOWLEDGEMENTS

We are grateful to the Medical Research Council of Canada (Grant MA-5965) for financial support of this work.

#### REFERENCES

- Abrams D.N., Knaus E.E., McQuarrie S.A., and Wiebe L.I. The Chemistry of Radiopharmaceuticals (N.D. Heindel <u>et al</u>, Ed), Masson Publishing USA Inc., N.Y. (1978), p. 205.
- 2. Kriss J.P. and Revesz L. Cancer Res. 22:254 (1962).
- 3. Wong S. and Ache H.J. Int. J. Appl. Radiat. Isotopes 27:19 (1976).
- 4. Anghileri L.J. and Heidbreder M. Nucl.-Med. Bd. XV/Heft 5 (1976).
- 5. Presented in part at the Second International Symposium on Radiopharmaceutical Chemistry, Oxford, England, July 3-7, 1978.
- 6. Stocklin G. Int. J. Appl. Radiat. Isotopes 28:131 (1977).
- Spicer J.A., Preston D.F., Robinson, R.G., Bradshaw D.L., Stern S.H., Dean R.D., Martin N.L., and Rhodes B.A. - Int. J. Appl. Radiat. Isotopes <u>28</u>:163 (1977).
- 8. Codington J.F., Doerr I.L. and Fox J.J. J. Org. Chem. 29:558 (1964).
- 9. Hampton A. and Nichol A.W. Biochem. <u>5</u>: 2076 (1966).
- 10. Codington J.F., Doerr I.L. and Fox J.J. J. Org. Chem. 29:564 (1964).
- Vogel, A.I., A Textbook of Quantitative Inorganic Analysis, Longmans, Green and Co., 3rd Ed., London, p. 254, p. 261 (1961).